MY186779A - Nucleic acid derivative having immunostimulatory activity - Google Patents
Nucleic acid derivative having immunostimulatory activityInfo
- Publication number
- MY186779A MY186779A MYPI2019004986A MYPI2019004986A MY186779A MY 186779 A MY186779 A MY 186779A MY PI2019004986 A MYPI2019004986 A MY PI2019004986A MY PI2019004986 A MYPI2019004986 A MY PI2019004986A MY 186779 A MY186779 A MY 186779A
- Authority
- MY
- Malaysia
- Prior art keywords
- nucleic acid
- acid derivative
- strand
- immunostimulatory activity
- nucleotides
- Prior art date
Links
- 230000003308 immunostimulating effect Effects 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 5
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The purpose of the present invention is to provide double-stranded oligonucleotides comprising the CpG oligonucleotide mentioned below, as a nucleic acid derivative having an immunostimulatory activity. An adjuvant comprising a double-stranded oligonucleotide, wherein a first strand is a CpG oligonucleotide consisting of 8 to 50 nucleotides, a second strand is an oligonucleotide consisting of 8 to 60 nucleotides and comprising a sequence capable of hybridizing with the first strand, and a lipid binds to the second strand through a linker.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2017/013025 WO2018179172A1 (en) | 2017-03-29 | 2017-03-29 | Nucleic acid derivative having immunostimulatory activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY186779A true MY186779A (en) | 2021-08-19 |
Family
ID=63674710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019004986A MY186779A (en) | 2017-03-29 | 2017-03-29 | Nucleic acid derivative having immunostimulatory activity |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JP6611298B2 (en) |
| BR (1) | BR112019019177B8 (en) |
| IL (1) | IL268983B2 (en) |
| MY (1) | MY186779A (en) |
| PH (1) | PH12019502063A1 (en) |
| SG (1) | SG11201908059YA (en) |
| WO (1) | WO2018179172A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR114990A1 (en) | 2017-11-02 | 2020-11-18 | Alios Biopharma Inc | OLIGONUCLEOTIDE CONSTRUCTS AND USES OF THEM |
| WO2020246443A1 (en) | 2019-06-03 | 2020-12-10 | 塩野義製薬株式会社 | Production method for bifurcated lipid-linked oligonucleotide, and intermediate |
| EP3892260A1 (en) * | 2020-04-10 | 2021-10-13 | Bayer Animal Health GmbH | Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids |
| JPWO2022054207A1 (en) * | 2020-09-10 | 2022-03-17 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2314693A3 (en) * | 1999-08-13 | 2012-11-28 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| AU2003203079B8 (en) * | 2002-02-04 | 2009-01-15 | Oncothyreon Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
| GB0605247D0 (en) * | 2006-03-15 | 2006-04-26 | Chiron Srl | Compositions and methods for immunisation |
| MX2011002267A (en) * | 2008-08-28 | 2011-03-30 | Glaxosmithkline Biolog Sa | Vaccine. |
| MX337723B (en) * | 2008-12-09 | 2016-03-15 | Pfizer Vaccines Llc | IgE CH3 PEPTIDE VACCINE. |
| WO2013151771A1 (en) * | 2012-04-05 | 2013-10-10 | Massachusetts Institute Of Technology | Immunostimulatory compositions and methods of use thereof |
| WO2015105083A1 (en) * | 2014-01-07 | 2015-07-16 | 塩野義製薬株式会社 | Double-stranded oligonucleotide containing antisense oligonucleotide and sugar derivative |
-
2017
- 2017-03-29 IL IL268983A patent/IL268983B2/en unknown
- 2017-03-29 WO PCT/JP2017/013025 patent/WO2018179172A1/en not_active Ceased
- 2017-03-29 JP JP2019508453A patent/JP6611298B2/en active Active
- 2017-03-29 BR BR112019019177A patent/BR112019019177B8/en active IP Right Grant
- 2017-03-29 MY MYPI2019004986A patent/MY186779A/en unknown
- 2017-03-29 SG SG11201908059Y patent/SG11201908059YA/en unknown
-
2019
- 2019-09-11 PH PH12019502063A patent/PH12019502063A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019019177A2 (en) | 2020-04-14 |
| BR112019019177B8 (en) | 2022-09-13 |
| IL268983B2 (en) | 2024-07-01 |
| BR112019019177B1 (en) | 2021-05-11 |
| PH12019502063A1 (en) | 2020-09-28 |
| JPWO2018179172A1 (en) | 2020-02-06 |
| IL268983B1 (en) | 2024-03-01 |
| WO2018179172A1 (en) | 2018-10-04 |
| SG11201908059YA (en) | 2019-10-30 |
| JP6611298B2 (en) | 2019-11-27 |
| IL268983A (en) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX374553B (en) | NUCLEIC ACID DERIVATIVE THAT HAS IMMUNOSTIMILATORY ACTIVITY. | |
| MX2010004452A (en) | Lipid-modified double-stranded rna having potent rna interference effect. | |
| JP2016526529A5 (en) | ||
| JP2015142558A5 (en) | ||
| WO2016140726A3 (en) | Triggered assembly of metafluorophores | |
| EA201791820A1 (en) | OLIGONUCLEOTIC THERAPY OF CONGENITAL AMAUROSIS LEBER | |
| AU2014219019A8 (en) | Short interfering nucleic acid (siNA) molecules containing a 2' internucleoside linkage | |
| HK1216535A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| UA100727C2 (en) | Compound containing modified oligonucleotide complementary to mir-21 or its precursor, for treatment, prevention or diagnostics of fibrosis or fibroproliferative disease | |
| MX344972B (en) | Immunostimulatory oligonucleotides. | |
| BR112015024764A2 (en) | modified tgf-beta oligonucleotides | |
| PH12019502063A1 (en) | Nucleic acid derivative having immunostimulatory activity | |
| EP4585686A3 (en) | Modified double-stranded rna agents | |
| NZ563845A (en) | RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic | |
| SG10201705285SA (en) | Antisense oligonucleotides | |
| HK1221978A1 (en) | Tmprss6 irna compositions and methods of use thereof | |
| HK1203075A1 (en) | Substituted phosphorothioate nucleotide analogs | |
| MY196912A (en) | Short pendant arm linkers for nucleotides in sequencing applications | |
| AR100946A1 (en) | COMPOSITIONS AND METHODS TO REGULATE GENE EXPRESSION THROUGH RNA INTERFERENCE | |
| WO2022084331A3 (en) | Novel ligands for asialoglycoprotein receptor | |
| PE20211238A1 (en) | ANTI-SENSE TREATMENT OF ANGELMAN SYNDROME | |
| AR083445A1 (en) | siRNA AGAINST FIBROSIS | |
| MX377713B (en) | NOTCH 1 SPECIFIC INTERFERING SMALL RIBONUCLEIC ACID MOLECULES. | |
| EP3822350A4 (en) | NUCLEIC ACID INDUCING RNA INTERFERENCE INHIBITING NON-CANONICAL MICRORNA TARGETS, AND USE THEREOF | |
| JP2016108250A5 (en) |